<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451228</url>
  </required_header>
  <id_info>
    <org_study_id>15-0067</org_study_id>
    <secondary_id>1R01HD083003-01</secondary_id>
    <nct_id>NCT02451228</nct_id>
  </id_info>
  <brief_title>Indomethacin PK and PD Therapy in Pregnancy</brief_title>
  <official_title>Pharmacokinetic and Pharmacogenomic Approach to Indomethacin Therapy in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will follow pregnant women who are taking indomethacin for preterm labor to find
      out the pharmacokinetics (what the body does to the drug) and pharmacodynamics (effectiveness
      of the drug in treating the specific intended disease process) of this medication. This will
      help us develop more information for medication dosing specific to pregnant women
      experiencing preterm labor.

      Indomethacin is often prescribed to pregnant women presenting with preterm labor or shortened
      cervix, which places them at risk for preterm labor and delivery. Indomethacin has been used
      since the 1970s to prolong pregnancy by decreasing uterine contractions. However, despite the
      widespread use of indomethacin in pregnancy, there is limited information available to help
      physicians determine how much indomethacin to prescribe and how often to prescribe it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the pharmacokinetics, pharmacodynamics and pharmacogenomics of Indomethacin in
      pregnant patients with the hypothesis that that estradiol levels during pregnancy (12-32
      weeks of gestation) and CYP2C9 polymorphisms affect the PK of indomethacin, and subsequently,
      the response to indomethacin therapy in patients at risk of PTB. This hypothesis will be
      tested with the following specific aims: (1) Determine the PK of indomethacin in pregnant
      women at risk of PTB and its PD effects on reducing the rate of PTB before 34 weeks of
      gestation, as well as any associations between the PK and secondary maternal/neonatal
      clinical outcomes; (2) Determine the effects of maternal levels of estradiol in mid-pregnancy
      and CYP2C9 polymorphisms on indomethacin biotransformation to O-desmethylindomethacin in
      pregnant patients; (3) Construct a population PK/PD model of indomethacin in patients at risk
      of PTB (12-32 weeks of gestation) in order to optimize the dose and the dosing frequency for
      indomethacin prescribed to each individual based on covariates such as race/ethnicity, CYP2C9
      genotype, gestational age, estradiol levels, smoking status, and body mass index (BMI). The
      investigators will enroll 300 subjects with sPTL or shortened cervix in a prospective
      opportunistic PK study designed to correlate the PK of indomethacin, patient genotype, and
      clinical outcomes. The investigators will merge dosing, sampling, demographic, and clinical
      information with the drug concentration data and use population PK methodologies to analyze
      the data using nonlinear mixed effect modeling. Quantification of the differences within and
      between individuals allows for identification of covariates (e.g., CYP2C9 genotype, estradiol
      levels, BMI, etc.) that can explain variability and affect drug exposure. These covariates,
      if significant, can then be used in the future to optimize dosing in individual patients at
      risk for PTB. Achieving this goal of individualized indomethacin therapy could have a
      significant impact on clinical practice and improve maternal and neonatal outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery &lt;34 weeks gestation</measure>
    <time_frame>Delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery &lt;37, 32, and 28 weeks gestation</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of pregnancy by 48 hours after enrollment (for sPTL)</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chorioamnionitis</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm premature rupture of membranes</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oligohydramnios</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary edema</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Death</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar scores</measure>
    <time_frame>Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal or neonatal death</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission and length of stay in the NICU</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proven neonatal sepsis by culture</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory distress syndrome</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patent ductus arteriosus</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periventricular leukomalacia</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular hemorrhage</measure>
    <time_frame>Delivery and up to 120 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Premature Labor</condition>
  <condition>Pregnancy</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Single-group</arm_group_label>
    <description>No intervention; Observational study of 300 pregnant women receiving Indomethacin therapy for risk of preterm birth</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal Venous Blood for serum Maternal Blood for DNA (for CYP2C9) Maternal Urine Cord Blood
      (Umbilical Vein and Artery) for serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multi-center study including 300 pregnant women between 12-32 weeks of gestation
        at risk of PTB (sPTL or shortened cervix with or without funneling membranes) or other
        conditions to whom indomethacin is prescribed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be enrolled in the study, patients must meet all of the following criteria:

          1. Age at least 18 years

          2. Singleton gestation

          3. 12 0/7 to 32 0/7 weeks gestation (see Gestational Age Determination section 3.2.1.1)

          4. Patient receiving indomethacin for any of the following diagnoses:

               1. Preterm labor: regular uterine contractions with documented cervical change or
                  dilatation â‰¥ 2 cm and 80% effacement

               2. Cervical shortening (&lt; 2.5 cm documented on transvaginal ultrasound) with or
                  without funneling membranes

               3. Planned cervical cerclage or emergent cerclage

               4. Other condition whereby Indomethacin is indicated

          5. Maternal and fetal condition allows anticipated delay of delivery for more than 24
             hours -

        Exclusion Criteria:

          -  Exclusion criteria include:

               1. Contraindications to indomethacin use (history of maternal bleeding disorder,
                  thrombocytopenia, maternal hepatic, gastrointestinal ulcerative, or renal
                  dysfunction, asthma)

               2. Known fetal abnormality, genetic syndrome, or intrauterine fetal demise

               3. Anticipated delivery in less than 24 hours, cervical dilatation &gt; 6 cm

               4. Preterm premature rupture of membranes

               5. Suspected chorioamnionitis

               6. Oligohydramnios (DVP &lt; 2 cm)

               7. Congenital Uterine anomaly

               8. Vaginal bleeding due to suspected placental abruption or placenta previa

               9. Planned preterm delivery for maternal/fetal indications

              10. Non-reassuring fetal status

              11. Planned delivery outside UTMB or participation in another intervention trial
                  which may affect maternal or neonatal outcomes

              12. Unsure gestational age due to possibility of intrauterine growth restriction

              13. Hematocrit &lt;28% (as determined by most recent result within 1 month of
                  enrollment)

              14. Prisoners
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary DV Hankins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Rytting, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly A West, DHEd, PA-C</last_name>
    <phone>409-747-8234</phone>
    <email>hawest@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley Salazar, NP</last_name>
    <phone>409-772-0312</phone>
    <email>assala@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Dimperio</last_name>
      <phone>205-934-3276</phone>
      <email>ldimperio@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Saxon, RN</last_name>
      <email>nbsaxon@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Tita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelia Sutton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Wen, MD</last_name>
      <email>twen@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Latasha Cox, MHSA</last_name>
      <phone>601-815-5018</phone>
      <email>lcox2@umc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tony Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Torres</last_name>
      <phone>212-305-2158</phone>
      <email>ct2179@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Kirsten Cleary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Weaver</last_name>
      <phone>919-681-0308</phone>
      <email>kristin.weaver@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Chad Grotegut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch, Dept of OB/GYN</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly West, DHEd, PA-C</last_name>
      <phone>409-747-8234</phone>
      <email>hawest@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Salazar, WHNP</last_name>
      <phone>409-772-0312</phone>
      <email>assala@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Hankins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Rytting, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maged Costantine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shannon Clark, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Nanovskaya, DDS, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Cohen-Wolkowiez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Gibson</last_name>
      <phone>801-213-2845</phone>
      <email>Marie.Gibson@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Erin Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Medical Branch, Galveston</investigator_affiliation>
    <investigator_full_name>Gary Hankins</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Preterm labor</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Short Cervix</keyword>
  <keyword>CYP2C9 Genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Once published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

